Dr. Michael Birrer Treatments Targeting Either VEGF or ANG2 in Gynecologic Cancers
Michael Birrer, MD, PhD, on treatments targeting either VEGF or ANG2 in gynecologic cancers.
Michael Birrer, MD, PhD, director, Medical Gynecologic Oncology Director, Gynecologic Oncology Research Program, Massachusetts General Hospital Cancer Center, professor of Medicine, Harvard Medical School, on treatments targeting either VEGF or ANG2 in gynecologic cancers.
Birrer says VEGF stimulates tumor vessel growth, while ANG2 stabilizes the vessels, making both an attractive target for oncologists. Birrer adds that to date, ANG2-targeted therapies have not been as successful in trials as VEGF-targeted therapies. ANG2-targeted therapies have given patients a better progression-free survival, but the treatment has not affected patients’ overall survival rates, he says.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
